Recurrent and Nonrecurrent Condyloma Treatment
Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma
Treatment is considered successful if the difference in the response in the reduction of the affected area is above 30% for any of the doses compared to placebo Patients will be randomised to 1 of 3 treatment arms
- Placebo
- CIGB-300 - 5 mg
- CIGB-300 - 15 mg
A two week screening visit will take place to assess patient eligibility, at least 2 to 5 target lesions (area of the lesion between 20 to 80 mm2), should be identified. Patients included in the study will be randomly assigned to one of three study arms. Treatment consists of 3 perilesional applications at the base of the target lesion every 48 hours with a window of ±24hs.
After each application the potential local and systemic adverse events will be identified and monitored.
After the last application is made, weekly clinical evaluations for 3 weeks and then every two weeks, until week 12 will take place. At this time, clinical assessment of efficacy will be carried out that will define the response to treatment.
After this visit, patients will be followed every 3 months until one year after the last treatment has been completed to confirm response and long-term security of the CIGB-300 application.
At screening, at 2 and 8 weeks as well as at 6 and 12 months post-treatment blood studies will be conducted to assess the safety from the systemic point of view.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Buenos Aires
-
Capital Federal, Buenos Aires, Argentina, C1417AZE
- Laboratorio Elea SACIFyA
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Informed consent signed by the patient
- Women with clinical diagnosis of recurrent and non recurrent genital condyloma
- Presence of a condylomatous lesion or area of external confluent condylomatous lesions of not less than 20 or more than 80 mm2
- The number of warts should be between 2 and 20
- External genital warts or in perigenital regions
- Negative pregnancy test
- Age between 18 and 65 years inclusive
Exclusion Criteria:
- Having received surgery treatment, ablative or immunomodulator treatment during the 30 days prior to inclusion
- Presence of genital warts only located in the cervix, vagina, bladder or rectum
- Pregnancy and lactation
- Patients of childbearing age who are not using an adequate contraception method during treatment to prevent pregnancy.
- Inadequately controlled chronic diseases (hypertension, diabetes, chronic kidney failure, heart failure, hyperthyroidism, malignant neoplasms, epilepsy, severe mental depression)
- Patients with previous diagnosis of bleeding disorders and other chronic blood disorders (von Willebrand disease, haemophilia, leukaemia) or use of anticoagulants within 30 days before the study
- Current genital herpes, which requires application of topical antivirals
- Immunosuppressive disease, current intake of immunosuppressive/ immunomodulatory drugs within 30 days before the study.
- Autoimmune Diseases (Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Diabetes)
- Severe allergy history as urticaria, dermatitis or persistent bronchitis and bronchial asthma
- Febrile illness (temperature greater than 38ºC) at the time or within 24 hours prior to administration of the product or suspected acute infectious disease by clinical examination
- Diseases that compromise the patient's consciousness or the ability to give informed consent or to collaborate in the study
- Concomitant skin lesions that prevent the administration of condylomatous lesions at the proposed site
- Participating in another clinical trial
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
|
|
Eksperimentell: CIGB-300 - 5 mg
|
CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
|
|
Eksperimentell: CIGB-300 - 15 mg
|
CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of patients with complete response of target lesion in each study group
Tidsramme: Up to one year
|
Up to one year
|
|
Number of patients with adverse events during the application of the study drug
Tidsramme: Up to one year
|
Up to one year
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Effect of the perilesional application of CIGB300 in the reduction in the number and area of genital warts lesions treated directly
Tidsramme: Up to one year
|
Up to one year
|
|
Locoregional effect of CIGB300 by assessing the area and number of genital warts lesions not directly treated
Tidsramme: Up to one year
|
Up to one year
|
|
Effect of CIGB300 to avoid recurrence of the lesions
Tidsramme: Up to one year
|
Up to one year
|
|
Optimal dose, in comparison with placebo
Tidsramme: Up to one year
|
Up to one year
|
|
Number of patients with adverse events
Tidsramme: Up to one year
|
Up to one year
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Hudsykdommer
- Virussykdommer
- Infeksjoner
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Sykdomsattributter
- DNA-virusinfeksjoner
- Hudsykdommer, smittsomme
- Vorter
- Papillomavirusinfeksjoner
- Hudsykdommer, viral
- Tumorvirusinfeksjoner
- Tilbakefall
- Condylomata Acuminata
Andre studie-ID-numre
- CONDI 02 AR
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på PROAPOPTOTIC PEPTIDE CIGB 300
-
Janssen-Cilag International NVFullført
-
Ludwig-Maximilians - University of MunichGerman Research Foundation; Merck Sharp & Dohme LLCFullført